H.C. Wainwright lowered the firm’s price target on Immunovant (IMVT) to $35 from $51 and keeps a Buy rating on the shares. The target cut reflects the company’s data readouts in 2027, with an expected potential launch in 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s Strategic Developments and Financial Strength Justify Buy Rating
- Immunovant, Inc. Reports Strategic Progress and Financial Results
- Immunovant reports Q4 EPS (64c), consensus (72c)
- Immunovant sees cash runway through GD readout expected in 2027
- IMVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?